Understanding HRD Testing for Ovarian Cancer: A Guide for Indian Women

What is HRD Testing for Ovarian Cancer?

Ovarian cancer is a serious health concern, and understanding the latest diagnostic tools is crucial for effective management. Homologous Recombination Deficiency (HRD) testing is a significant advancement in this area. It’s a test that looks at how your body repairs damaged DNA, a process that can be compromised in ovarian cancer. By assessing this repair mechanism, HRD testing helps doctors understand the potential progression of ovarian cancer and guides treatment decisions, especially for High-Grade Serous Ovarian Cancer (HGSOC), which accounts for a large percentage of ovarian cancers and has a high mortality rate. This guide will explain HRD testing in simple terms, its importance, how it's done, and what the results mean for women in India.

Why is HRD Testing Important for Ovarian Cancer?

Ovarian cancer, particularly HGSOC, is often diagnosed at later stages, making treatment more challenging. HRD testing acts as a biomarker, a measurable indicator that can help predict how a cancer might behave and how it might respond to certain treatments. Approximately 50% of HGSOC tumors are HRD-positive, meaning their DNA repair mechanisms are faulty. This information is invaluable for several reasons:

• Predicting Cancer Progression: HRD status can give doctors insights into the likelihood of the cancer advancing.
• Guiding Treatment Decisions: HRD-positive tumors often respond well to specific targeted therapies, such as PARP inhibitors, and platinum-based chemotherapy. Identifying a patient as a candidate for these treatments early can significantly improve outcomes.
• Personalized Medicine: HRD testing allows for a more personalized approach to cancer treatment, ensuring that patients receive therapies most likely to be effective for their specific type of cancer.

Understanding DNA Repair and HRD

Our bodies have natural mechanisms to repair damaged DNA. One crucial pathway is the Homologous Recombination Repair (HRR) pathway. Think of it like an engineer using blueprints (a healthy copy of a gene) to fix a damaged structure (a damaged gene). When this HRR pathway functions correctly, it accurately repairs DNA breaks. However, in some cancers, including ovarian cancer, this pathway can be deficient (HRD). This deficiency means that DNA damage isn't repaired properly, leading to an accumulation of errors, or mutations, in the DNA. Over time, these unrepaired mutations can become 'genomic scars' and drive the growth and spread of cancer cells.

What Does HRD Testing Look For?

HRD testing typically involves analyzing a tissue sample from the tumor. The test looks for specific indicators of faulty DNA repair, including:

• Large-Scale Transitions (LST): These are significant breaks in chromosomes that result in large fragments being left behind. They are a sign of chromosomal instability, indicating that the DNA structure is breaking down.
• Loss of Heterozygosity (gLOH): This refers to the irreversible loss of one of the two copies of a gene that a person inherits from their parents. When this happens at specific locations in the DNA, it can signal a problem with repair.
• The Number of Telemetric Imbalances (TAI): Telomeres are protective caps at the ends of chromosomes. Imbalances in these regions can indicate instability and errors in DNA replication and repair.

The results of these analyses are used to calculate an HRD score. A score of 42 or greater is generally considered positive, indicating HRD.

Germline vs. Somatic Testing

It's important to distinguish between two types of genetic testing relevant to ovarian cancer:

• Germline Testing: This test checks for inherited mutations in genes like BRCA1 and BRCA2. These mutations are present in all cells of the body from birth and significantly increase the risk of developing certain cancers, including ovarian and breast cancer.
• Somatic Testing (Tumor Testing): This is what HRD testing primarily involves. It analyzes the genetic makeup of the tumor itself to identify acquired mutations and assess the HRR pathway's function.

While only about 10% of ovarian cancers are linked to inherited BRCA mutations, HRD testing can identify a larger group of patients (up to 50% of HGSOC) who may benefit from specific treatments, regardless of whether they have an inherited BRCA mutation.

How is HRD Testing Performed?

HRD testing is usually performed on a tissue sample obtained during or after an ovarian cancer diagnosis. Your doctor may recommend a biopsy or a surgical procedure to collect this sample. The collected tissue is then sent to a laboratory for analysis. The lab examines the sample for the genetic markers and genomic scars associated with HRD, as described earlier. The process is generally straightforward and is a crucial part of the diagnostic workup for ovarian cancer.

Interpreting HRD Test Results

The results of the HRD test are typically presented as an HRD score. As mentioned, a score of 42 or higher is generally considered positive for HRD. Here’s what this means:

• HRD-Positive Result (Score >= 42): If your HRD score is 42 or greater, it indicates that your tumor has a deficiency in DNA repair. This often means you are a good candidate for treatment with PARP inhibitors and platinum-based chemotherapy. These treatments are particularly effective against HRD-positive cancers.
• HRD-Negative Result (Score < 42): A score below 42 suggests that your tumor's DNA repair mechanisms are functioning adequately. In this case, other treatment options might be considered, and PARP inhibitors might be less effective.

Important Note: Even if your HRD score is below 42, if you have tested positive for inherited BRCA mutations (through germline testing), you might still be a candidate for PARP inhibitor treatment. This highlights the importance of considering both germline and HRD testing results together.

Treatment Implications: PARP Inhibitors and Chemotherapy

The most significant impact of HRD testing is its role in guiding treatment with PARP inhibitors. These drugs work by blocking another DNA repair pathway, making it impossible for cancer cells with faulty HRR (i.e., HRD-positive) to survive. They are a form of targeted therapy, meaning they specifically attack cancer cells while sparing healthy cells as much as possible.

HRD-positive status also indicates that a tumor is likely to respond well to platinum-based chemotherapy. This is a standard treatment for ovarian cancer, and knowing the HRD status can help confirm its suitability.

When to Consult a Doctor

It is essential to consult a doctor if you experience any symptoms suggestive of ovarian cancer, such as:

• Persistent bloating
• Pelvic or abdominal pain
• Difficulty eating or feeling full quickly
• Feeling very tired
• Changes in bowel or bladder habits

If you have a family history of ovarian, breast, or other related cancers, it is also crucial to discuss genetic testing and HRD screening with your doctor. Early detection and appropriate testing can lead to better treatment outcomes. Do not hesitate to seek medical advice if you have concerns about your reproductive health or any symptoms that worry you.

Prevention and Lifestyle

While HRD testing is a diagnostic and treatment tool, general lifestyle choices can play a role in overall health and potentially reduce cancer risk. Maintaining a balanced diet, regular physical activity, and avoiding smoking are always recommended. For women with a high genetic risk, regular screening as advised by a healthcare professional is paramount.

Conclusion

HRD testing represents a significant step forward in the fight against ovarian cancer. By providing detailed information about a tumor's DNA repair capabilities, it empowers doctors to make more informed treatment decisions, particularly regarding the use of PARP inhibitors and chemotherapy. For women in India, understanding this technology can lead to more effective and personalized care. Always discuss your health concerns and any potential testing with your healthcare provider for the best possible outcomes.